News

In TALAPRO-3, adding talazoparib to enzalutamide cut the risk of radiographic progression or death by 52%; anemia was the leading toxicity.

A Fox Chase intervention raised trial-naïve patients' understanding of placebo use and randomization; its effect on enrollment is still untested.

Divarasib beat first-generation KRAS G12C inhibitors in NSCLC, while new data on olomorasib, daraxonrasib, and a KRAS G12D inhibitor expand the field.

Yingzi Zhang, PhD, RN, discusses anxiety and depression data from 21,206 oncology patients ahead of the ANE Research Symposium.

Stepped care for fear of cancer recurrence was rated feasible by most clinicians, while training all staff to screen was rated least feasible.

A breast surgeon explains how nurses can build baseline bioimpedance screening and long-term lymphedema surveillance into clinic workflows.

Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.

Dana-Farber nurse practitioners outline ADC patient selection, sequencing, ILD surveillance, and patient education from JADPRO Live 2026.

Brianne Whitley, CNP, of Dana-Farber, shares strategies for hot flashes, sexual health, survivorship planning, and clinical trial access for men.

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after platinum-based chemotherapy.

Explore how nurses support kidney transplant candidates diagnosed with renal cell carcinoma, covering early detection, treatment options, and care.

Dana-Farber's Brianne Whitley, CNP, details red-flag symptoms, ER-positive biology, and why every man with breast cancer needs a genetic referral.

European survey reveals how oncology nurses manage complex multiple myeloma care amid time and resource constraints.

Leslie Smith, DNP, discusses mediating trial care, vetting protocols for nursing scope of practice, and guiding frontline nurses toward research.

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.

ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.

Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.

The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

Eppie Bass, APRN, explains how nurses can counsel patients on flu-like symptoms vs warning signs with nogapendekin alfa inbakicept-pmln and BCG.

Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.

Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.

A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.

Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS efficacy data.

FDA-approved subcutaneous isatuximab via on-body injector changes myeloma care workflows. Experts outline what nurses and PAs need to know.

For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker testing, and support.

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.